
908 Devices (MASS) Stock Forecast & Price Target
908 Devices (MASS) Analyst Ratings
Bulls say
908 Devices Inc. is positioned favorably due to heightened growth prospects in its Handheld segment, bolstered by the recent acquisition of RedWave, which is anticipated to contribute $11 million to FY24 revenue with a growth rate exceeding 20%. Improvements in product technology and operational efficiencies are expected to drive demand and lead to a resurgence in Desktop revenues, ultimately enhancing overall cash flow. The CEO's recent stock purchases indicate strong confidence in the company’s forward momentum, reinforcing the belief in 908 Devices' positive trajectory within its market sectors.
Bears say
908 Devices Inc faces several challenges that contribute to a negative financial outlook. Firstly, a potential slowdown in cell and gene therapy spending could negatively impact growth expectations, particularly if funding within the biotech sector declines or if bioprocessing growth does not meet investor expectations. Additionally, delays in reimbursement for Exosome tests and tightened research budgets in academic institutions pose further risks to revenue growth, which are compounded by currency fluctuations from international operations.
This aggregate rating is based on analysts' research of 908 Devices and is not a guaranteed prediction by Public.com or investment advice.
908 Devices (MASS) Analyst Forecast & Price Prediction
Start investing in 908 Devices (MASS)
Order type
Buy in
Order amount
Est. shares
0 shares